This study focuses on patients with Chronic Spontaneous Urticaria, a condition that causes recurring hives and itching without a known trigger. The study will evaluate a medication called remibrutinib (also known as LOU064), which is taken as a film-coated tablet by mouth. Some participants will receive the actual medication, while others will receive a placebo.
The purpose of this research is to assess how well remibrutinib works over an extended period in patients who have already participated in previous studies of this medication. During the study, patients who showed improvement in their symptoms will either continue taking remibrutinib or switch to placebo. The researchers will monitor how long it takes for symptoms to return, if they do.
Throughout the study, participants may also receive other common treatments for their condition, including antihistamines (medications that reduce allergic symptoms) and corticosteroids (medications that reduce inflammation). The study will track any side effects that occur during the treatment period. The total duration of treatment may last up to 160 weeks, depending on the participant’s response to the medication.
Bulgaria 
Czechia 
Denmark 
France 
Germany 
Hungary 
Italy 
Poland 
Slovakia 
Spain